Zombie funds continue to plague the hedge fund world and are gradually extending their reach into the private equity market. Investors and managers alike face a number of choices and dilemmas when approaching existing portfolio investments in these zombie funds, whether that means litigation, liquidation or transferring limited partner interests through secondary market sell offs. The ultimate question is this: kill or cure?
Kinetic Partners’ Global Head of Corporate Recovery, Geoff Varga, and Jonathan Sablone of Nixon Peabody spoke with “Hedgeweek” and discussed the various challenges associated with zombie funds, as well as what steps the industry ought to take next to address these issues.
To read the full article, please click here.
